Publication date: 03/11/2017
Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the launch of an exercise period of its warrant plan initiated on 2 March 2015.
The warrant plan issued 1,089 warrants, entitling their holders to subscribe for a total number of 1,796,850 securities carrying voting rights (all ordinary shares), and exercisable in principle as from 1 January 2019. Pursuant to the conditions of the warrant plan, the current warrant exercise is triggered by the capital increase by way of a Private Placement executed on June 23, 2017, and approved by Mithra’s Board of Directors.
Based on the information received from warrant holders, Mithra expects to issue a maximum of 724,350 new shares which would result in a total share count of 34,967,081 ordinary shares. The outstanding warrants would remain exercisable as from 1 January 2019.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. JeanMichel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: